Youth clinical trials

Explore recruiting youth clinical trials.

Recruiting youth studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Youth trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to less than 18 Years of age With Generalized Myasthenia Gravis (gMG)

Spain, Italy, Poland, France

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects with Neuromyelitis Optica Spectrum Disorder

Spain, Poland, Sweden, Netherlands, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, placebo-controlled, double-blind, 2-period cross-over study in youth with autism spectrum disorders evaluating social and repetitive behaviors after four weeks of twice daily-doses of 24IU of intranasally administered oxytocin

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

Estrogen replacement therapy (ERT) for treatment of adolescent anorexia nervosa – An open label study

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, placebo-controlled, double-blind, 3-period cross-over study in youth with autism spectrum disorders evaluating neural plasticity and learning after a single administration of intranasal oxytocin

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE

Spain, Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

Youth trials by city

Youth in Toronto Youth in Vancouver Youth in Montreal Youth in Calgary Youth in Edmonton Youth in Ottawa Youth in Winnipeg Youth in Quebec City Youth in Hamilton Youth in Kitchener Youth in London Youth in Halifax Youth in New York Youth in Los Angeles Youth in Chicago Youth in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease